Search Results - "Cecchelli, R."

Stem Cell-Based Human Blood–Brain Barrier Models for Drug Discovery and Delivery.

Authors: Aday, S. Cecchelli, R. Hallier-Vanuxeem, D. et al.

Source: Trends in Biotechnology. May2016, Vol. 34 Issue 5, p382-393. 12p.

Subjects: Stem cells, Blood-brain barrier, Drug development, Drug delivery systems, Drug toxicity, Permeability (Biology)

Intercommunications between brain capillary endothelial cells and glial cells increase the transcellular permeability of the blood–brain barrier during ischaemia.

Authors: Brillault, J. Berezowski, V. Cecchelli, R. et al.

Source: Journal of Neurochemistry. 11/15/2002, Vol. 83 Issue 4, p807-817. 11p.

Increased transendothelial permeability of anti-cancer agent carboplatin with the aid of hyperbaric oxygenation.

Authors: Yamazaki, H. Shimizu, M. Murayama, N. et al.

Source: Xenobiotica. Oct2008, Vol. 38 Issue 10, p1298-1304. 7p. 2 Charts.

Accelerated Caco-2 cell permeability model for drug discovery.

Authors: Sevin, E. Dehouck, L. Fabulas-da Costa, A. et al.

Source: Journal of Pharmacological & Toxicological Methods. Nov2013, Vol. 68 Issue 3, p334-339. 6p.

In vitro blood–brain barrier model adapted to repeated-dose toxicological screening.

Authors: Fabulas-da Costa, A. Aijjou, R. Hachani, J. et al.

Source: Toxicology in Vitro. Sep2013, Vol. 27 Issue 6, p1944-1953. 10p.

The value of selected in vitro and in silico methods to predict acute oral toxicity in a regulatory context: Results from the European Project ACuteTox.

Authors: Prieto, P. Kinsner-Ovaskainen, A. Stanzel, S. et al.

Source: Toxicology in Vitro. Jun2013, Vol. 27 Issue 4, p1357-1376. 20p.

Brain pericytes ABCA1 expression mediates cholesterol efflux but not cellular amyloid-β peptide accumulation.

Authors: Saint-Pol J Vandenhaute E Boucau MC et al.

Source: Journal of Alzheimer's Disease. 2012, Vol. 28 Issue 1, p489-503. 15p.

Apical-to-Basolateral Transport of Amyloid-[beta] Peptides through Blood-Brain Barrier Cells is Mediated by the Receptor for Advanced Glycation End-Products and is Restricted by P-Glycoprotein.

Authors: Candela P Gosselet F Saint-Pol J et al.

Source: Journal of Alzheimer's Disease. 2010, Vol. 22 Issue 3, p849-859. 11p.

Highly purified lipoteichoic acid from gram-positive bacteria induces in vitro blood–brain barrier disruption through glia activation: Role of pro-inflammatory cytokines and nitric oxide

Authors: Boveri, M. Kinsner, A. Berezowski, V. et al.

Source: Neuroscience. Apr2006, Vol. 137 Issue 4, p1193-1209. 17p.

In vitro models for the blood–brain barrier

Authors: Garberg, P. Ball, M. Borg, N. et al.

Source: Toxicology in Vitro. Apr2005, Vol. 19 Issue 3, p299-334. 36p.

Neuroprotective properties of tianeptine: interactions with cytokines

Authors: Plaisant, F. Dommergues, M.-A. Spedding, M. et al.

Source: Neuropharmacology. May2003, Vol. 44 Issue 6, p801. 9p.

High transcytosis of melanotransferrin (P97) across the blood–brain barrier.

Authors: Demeule, M. Poirier, J. Jodoin, J. et al.

Source: Journal of Neurochemistry. 11/15/2002, Vol. 83 Issue 4, p924-933. 10p.

Ready-to-use in vitro blood–brain barrier model

Authors: Hallier-Vanuxeem, D. Dehouck, L. Sevin, E. et al.

Source: Toxicology Letters. Aug2011 Supplement, Vol. 205, pS161-S161. 1p.

In vitro blood–brain barrier model adapted to repeated dose toxicological screening

Authors: da Costa, A. Hachani, J. Landry, C. et al.

Source: Toxicology Letters. Aug2011 Supplement, Vol. 205, pS155-S156. 0p.

Screening of molecules through the BBB: involvement of drug efflux transporters.

Authors: Fenart, L. Berezowski, V. Dehouck, M. P. et al.

Source: Journal of Neurochemistry. 6/2/2003 Supplement 2, Vol. 85, p7-7. 1/4p.